CoChat

Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells

Open access
Kosowska, Agnieszka, Gallego-Colon, Enrique, Garczorz, Wojciech, Kłych-Ratuszny, Agnieszka, Aghdam, Mohammad Reza F, Woz´niak, Michał, Witek, Andrzej, Wróblewska-Czech, Agnieszka, Cygal, Anna, Wojnar, Jerzy, Francuz, Tomasz · 2017 · Endocrine Connections
Cited by 45

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Diabetes and cancer are prevalent diseases whose incidence is increasing globally. Diabetic women have a moderate risk increase in ovarian cancer, suggested to be due to an interaction between these two disorders. Furthermore, patients manifesting both diseases have associated worse prognosis, reduced survival and shorter relapse-free survival. According to current recommendations, incretin drugs such as Exenatide, a synthetic analog of Exendin-4, and Liraglutide are used as therapy for the type 2 diabetes (T2D). We studied the effects of GLP-1 and Exendin-4 on migration, apoptosis and metalloproteinase production in two human ovarian cancer cells (SKOV-3 and CAOV-3). Exendin-4 inhibited migration and promoted apoptosis through caspase 3/7 activation. Exendin-4 also modulated the expression of key metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2). Vascular endothelial cells, which contribute to the formation and progression of metastasis, were also analyzed. TNF-α-stimulated endothelial cells from iliac artery after Exendin-4 treatment showed reduced production of adhesion molecules (ICAM-1 and VCAM-1). Additionally, incretin treatment inhibited activation of apoptosis in TNF-α-stimulated endothelial cells. In the same experiment, MMPs (MMP-1 and MMP-9), which are relevant for tumor development, were also reduced. Our study demonstrated that incretin drugs may reduce cancer cell proliferation and dissemination potential, hence limiting the risk of metastasis in epithelial ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/ec-17-0294

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 45

Metadata

Authors
Kosowska, A., Gallego-Colon, E., Garczorz, W., Kłych-Ratuszny, A., Aghdam, M. R. F., Woz´niak, M., Witek, A., Wróblewska-Czech, A., Cygal, A., Wojnar, J., & Francuz, T.
Venue
Endocrine Connections
Published
2017-11
Volume
6
Issue
8
Pages
856-865
ISSN
2049-3614 (ISSN-L)
OpenAlex
W2765114354
Cited by
45
References
12
FWCI
0.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells. https://app.cochat.ai/papers/10.1530/ec-17-0294
The paper
Kosowska, A., Gallego-Colon, E., Garczorz, W., Kłych-Ratuszny, A., Aghdam, M. R. F., Woz´niak, M., Witek, A., Wróblewska-Czech, A., Cygal, A., Wojnar, J., & Francuz, T. (2017). Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells. Endocrine Connections. https://doi.org/10.1530/ec-17-0294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.